^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Korlym (mifepristone)

    i
    Other names: C-1073, C1073
    Associations

    News

    Trials
    Company:
    Corcept Therap
    Drug class:
    Progesterone receptor antagonist, GCR II antagonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers (clinicaltrials.gov)
    P1/2, N=65, Completed, Johns Hopkins University | Phase classification: P=N/A --> P1/2
    Phase classification
    |
    Korlym (mifepristone)
    9ms
    Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) (clinicaltrials.gov)
    P4, N=1000, Recruiting, Corcept Therapeutics | Trial primary completion date: Jan 2024 --> Mar 2024
    Trial primary completion date
    |
    Korlym (mifepristone)
    9ms
    INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers (clinicaltrials.gov)
    P=N/A, N=65, Completed, Johns Hopkins University | Recruiting --> Completed | N=150 --> 65
    Trial completion • Enrollment change
    |
    Korlym (mifepristone)
    9ms
    Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, University of Chicago | N=64 --> 29
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    albumin-bound paclitaxel • Korlym (mifepristone)
    1year
    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=201, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • AR (Androgen receptor)
    |
    PD-L1 expression • HER-2 negative • AR positive
    |
    carboplatin • paclitaxel • capecitabine • Xtandi (enzalutamide capsule) • Halaven (eribulin mesylate) • Korlym (mifepristone) • Mifeprex (mifepristone)
    almost2years
    Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=64, Active, not recruiting, University of Chicago | Trial primary completion date: Aug 2021 --> Dec 2022
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    albumin-bound paclitaxel • Korlym (mifepristone)
    almost2years
    GENETICALLY ENGINEERED HUMAN PITUITARY CORTICOTROPH TUMOR ORGANOIDS EXHIBIT DIVERGENT RESPONSES TO GLUCOCORTICOID RECEPTOR MODULATORS. (PubMed, Transl Res)
    Relacorilant sensitized PitNET organoid responsiveness to Pasireotide. Therefore, our study identified the potential therapeutic use of relacorilant in combination with somatostatin analogs and demonstrated the advantages of relacorilant over Mifepristone, supporting its further development for use in the treatment of CD patients.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
    |
    SSTR2 expression • SSTR5 expression
    |
    relacorilant (CORT125134) • Signifor (pasireotide) • Korlym (mifepristone) • Mifeprex (mifepristone)
    over2years
    Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=64, Active, not recruiting, University of Chicago | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2022 --> Aug 2021
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    albumin-bound paclitaxel • Korlym (mifepristone)
    over2years
    Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. (PubMed, Front Endocrinol (Lausanne))
    Glucocorticoid receptor (GR) antagonism with mifepristone has been shown to reverse the glucocorticoid-induced downregulation of SSTR2; however, the effects of GR modulation on SSTR2 expression in ACTH-secreting NETs, particularly corticotroph pituitary tumors, are not well known...Based on these findings, we propose that GR modulation in patients with ACTH-secreting NETs upregulates previously suppressed SSTR2s, resulting in tumor-specific antisecretory and anti-proliferative effects. The effect of relacorilant on pituitary corticotroph tumors is being investigated in an ongoing phase 3 study (NCT03697109; EudraCT 2018-003096-35).
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    SSTR2 expression • SSTR Expression
    |
    relacorilant (CORT125134) • Korlym (mifepristone) • Mifeprex (mifepristone)
    4years
    Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=3, Terminated, Check, Jerome H., M.D., Ph.D. | N=40 --> 3 | Trial completion date: Dec 2021 --> Oct 2020 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Oct 2020; Lack of enrollment
    Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK rearrangement • EGFR positive
    |
    Korlym (mifepristone)